Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Assertio Holdings Inc.

Assertio Therapeutics ( ($ASRT) ) has shared an update. On May 13, 2026, Assertio Holdings, Inc. agreed to be acquired by Zydus Worldwide DMCC, whi...

Assertio Therapeutics to be acquired by Zydus Worldwide

Assertio Therapeutics ( ($ASRT) ) just unveiled an update. On May 13, 2026, Assertio agreed to be acquired by Zydus Worldwide DMCC, which will laun...

Assertio Therapeutics to Be Acquired by Zydus Worldwide

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cencora (COR), LeonaBio (LONA) and Assertio Therapeutics (ASRT). ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (COR), LeonaBio (LONA) and Assertio Therapeutics (ASRT)

Assertio Therapeutics (ASRT) has disclosed a new risk, in the Debt & Financing category. Assertio Therapeutics remains exposed to pre-closing liabi...

Assertio Therapeutics’ Cosette Divestiture Leaves Material Legacy Liabilities and Indemnification Risks That Could Pressure Cash Flow and Valuation

Assertio Therapeutics ( ($ASRT) ) has shared an update. On May 5, 2026, Assertio Holdings announced that it had mutually agreed with Garda Therapeu...

Assertio Delays Tender Offers in Pending Garda Acquisition

Analysts fell to the sidelines weighing in on Waters (WAT) and Assertio Therapeutics (ASRT) with neutral ratings, indicating that the experts are n...

Analysts Offer Insights on Healthcare Companies: Waters (WAT) and Assertio Therapeutics (ASRT)

Assertio Therapeutics ( ($ASRT) ) just unveiled an update. Assertio Holdings, Inc. announced on May 4, 2026 that it entered into an amended and res...

Assertio Agrees to Enhanced All-Cash Acquisition by Garda

Assertio Therapeutics ( ($ASRT) ) has provided an update. On April 29, 2026, Assertio announced that it had mutually agreed with Garda Therapeutics...

Current Quarter	$-0.07	Next Quarter	$0.96
Current Year	$0.03	Next Year	$1.11
QoQ Growth	+1471.4%	YoY Growth	+3600.0%
3Y EPS CAGR	-97.2%	Target Price	$24.43
Consensus	Buy	Upside	+4.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ASRT	$23.44	+0.13%	398.18K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ASRT	$23.44	+0.1%	398.18K
3
4
5
6

ASRT

ASRT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Assertio Holdings Inc. Data in Excel

Get Assertio Holdings Inc. Data in Excel